Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PIK3R2 | O00459 | 9/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989258 | 0.88 | SLC2A1 (0.47) | SLC2A1MAPK1MAPKAPK2ALDH1A1MAPT | |
| SCHEMBL19988951 | 0.85 | ALDH1A1 (0.40) | SLC2A1MAPK1PIK3R2ALDH1A1MAPT | |
| SCHEMBL19989131 | 0.83 | PIK3R2 (0.42) | SLC2A1MAPK1PIK3R2MAPKAPK2MAPT | |
| SCHEMBL19989254 | 0.83 | PIK3R2 (0.42) | SLC2A1PIK3R2MAPKAPK2MAPT | |
| SCHEMBL19988892 | 0.83 | PIK3R2 (0.41) | SLC2A1MAPK1PIK3R2MAPT | |
| SCHEMBL19988870 | 0.81 | PIK3R2 (0.40) | PIK3R2MAPT | |
| SCHEMBL19989032 | 0.79 | PIK3R2 (0.42) | PIK3R2MAPT | |
| SCHEMBL19988909 | 0.78 | PIK3R2 (0.42) | PIK3R2MAPT | |
| SCHEMBL19989147 | 0.78 | PIK3R2 (0.42) | PIK3R2MAPT | |
| SCHEMBL19989245 | 0.73 | PIK3R2 (0.41) | MAPK1PIK3R2ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057808-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | SLC2A1 3011/4885MAPK1 106/4885PIK3R2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.